Pilot Study for Patients With Poor Response to Deferasirox
Completed · Phase 4
Conditions studied: Transfusion-dependent Hemachromatosis, Thalassemia Major, Sickle Cell Disease
In brief
This purpose of this study is to understand the differences between people who have a good response to deferasirox (exjade) compared to people who have a poor response to this medication when used for transfusion-dependent iron overload. The hypothesis is that patients with poor responses have physiologic barriers to deferasirox that may include absorption, pharmacokinetics of drug metabolism, hepatic clearance and/or genetic factors.
Key facts
- Study ID
- NCT00749515
- Run by
- Boston Children's Hospital
- People needed
- 15
- Starts
- 2008-03-01
- Expected to finish
- 2008-11-01
- Last updated by the study team
- 2024-02-12
Who can join
Age: 6 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Children's Hospital Boston — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.